Does Lurbinectedin Pose Risks During Pregnancy?
Lurbinectedin (brand name Zepzelca), approved for metastatic small cell lung cancer, carries significant pregnancy risks. It is classified as Pregnancy Category D by the FDA, indicating positive evidence of human fetal risk based on animal data and limited human reports, though potential benefits may warrant use in life-threatening situations.[1] The drug's prescribing information explicitly states it can cause fetal harm when administered to pregnant women.[2]
Animal Studies Showing Fetal Harm
In rats and rabbits, lurbinectedin at doses about 0.4 to 1 times the human clinical exposure caused embryo-fetal toxicity, including post-implantation loss, decreased fetal weight, and malformations like cleft palate and skeletal anomalies. Rabbits showed higher sensitivity, with abortions and total litter losses at lower doses.[2][3]
Human Pregnancy Data and Recommendations
No adequate controlled studies exist in pregnant women, but the label advises avoiding use during pregnancy. Women of reproductive potential must use effective contraception during treatment and for at least 6 months after the final dose. Men with female partners should use contraception during treatment and for 4 months post-dose. A pregnancy exposure registry (1-888-438-0439) tracks outcomes.[2]
What Happens if Exposed During Pregnancy?
Fetal exposure risks spontaneous abortion, congenital malformations, or growth restriction, similar to other alkylating-like agents. Verify pregnancy status before starting therapy. If exposure occurs, discuss risks with an obstetrician and consider ultrasound monitoring.[2][3]
Breastfeeding and Fertility Concerns
Lurbinectedin may pass into breast milk; breastfeeding is not recommended during treatment and for 2 weeks after. It may impair male and female fertility, potentially irreversible.[2]
Alternatives for Pregnant Patients with SCLC
Standard small cell lung cancer regimens like etoposide-platinum avoid pregnancy due to similar teratogenic risks. Supportive care or clinical trials may be considered; consult oncology guidelines for non-drug options in advanced cases.[1]
[1]: FDA Label for Zepzelca
[2]: Drugs.com - Lurbinectedin Pregnancy Info
[3]: Prescribers' Digital Reference (PDR) - Zepzelca